Home  ›  News  ›  Medicines and Therapeutics  ›  Dermatology  ›  AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis

AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis

Written by | 26 Mar 2021 | Dermatology

AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic arthritis. The updated Prescription Drug User Fee Act (PDUFA) action date has been extended three months to late Q2 2021.

AbbVie recently received an information request from the FDA for an updated assessment of the benefit-risk profile for upadacitinib in psoriatic arthritis. AbbVie responded to the request and the FDA will require additional time for a full review of the submission.

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.